Selection of Well-Tolerated GalNAc-siRNAs by Screening for RNAi-Mediated Off-Target Effects in Rodent Toxicity Studies Maja Janas, PhD, DABT
|
|
- Phillip Johnston
- 6 years ago
- Views:
Transcription
1 Selection of Well-Tolerated GalNAc-siRNAs by Screening for RNAi-Mediated Off-Target Effects in Rodent Toxicity Studies Maja Janas, PhD, DABT Senior Scientist, Investigative Toxicology TIDES, May 2 nd 2017
2 Agenda Nonclinical safety profile of GalNAc-siRNAs Mechanisms of GalNAc-siRNA hepatotoxicity in rodents 2
3 GalNAc-siRNA Conjugates SC-Administered Platform for Targeted Delivery to Hepatocytes sirna Metabolic stability Duration of effect Intrinsic potency Safety CMC Ligand Receptor affinity & specificity Metabolic stability Safety CMC Asialoglycoprotein Receptor (ASGPR) Highly expressed in hepatocytes High turnover (recycling time ~15 min) Conserved across species 3
4 GalNAc-siRNA Conjugates Nonclinical Considerations Highly specific distribution to liver via ASGPR Limited uptake/distribution in other organs Liver to kidney ratio >30 at PD doses Short plasma half-life; long tissue half-life; long PD effects Metabolized largely by intracellular exoand endo-nucleases Maximum liver drug concentration limits relevant toxicological doses Loss of dose-proportionality, approaching saturation of liver uptake via ASGPR Cannot achieve MTDs Excess circulating sirna levels not taken up by liver; excreted through kidneys 4
5 GalNAc-siRNA Conjugates Platform-Wide Responses at Toxicological Doses Rat Liver Hepatocellular vacuolation: increased number and size of normal rat hepatocellular vacuoles, most contain lipid Increased single cell necrosis Increased mitosis and regeneration Kidney Basophilic granules in proximal tubular epithelium; represents drug accumulation NHP Liver Basophilic granules in Kupffer cells and hepatocytes; represents drug accumulation Lymph nodes Vacuolated macrophages (with basophilic stippling); represents phagocytosis of drug Primarily dose-dependent and the result of drug accumulation in tissue 5
6 Path Towards a Development Candidate (DC) In silico prediction & In vitro efficacy In vitro screen for predicted off-targets Rodent Knockdown Rat >100x PD dose NHP Knockdown DC Good Actors (60%): No hepatotoxicity Bad Actors (40%): Show hepatotoxicity Single cell necrosis and/or hepatocellular degeneration with LFT 2x upper limit of normal 6
7 Potential Causes of Hepatotoxicity in Rodent Toxicity Studies RISC loading Illustrative design 1. Non-RNAi drug effects e.g. protein binding On-target binding Full sequence match mrna cleavage RISC mrna 3 -UTR 2. Competition for Ago binding with mirnas Off-target binding Partial sequence match 3. RNAi-mediated off-target activity 7 Desired on-target activity
8 n g A S / g liv e r u g A S / g liv e r 5 Modifications on the Antisense Strand Can Block RISC Loading With No Impact on Liver Exposure Dose: 30 mg/kg Regimen: q2d x 6 Necropsy: Day 15 RISC loading Sense strand removal Target RNA cleavage mrna R a t R IS C L o a d in g R a t L iv e r E x p o s u r e R IS C lo a d in g b lo c k R IS C lo a d in g b lo c k s ir N A -1 s ir N A -2 s ir N A -1 s ir N A -2 8
9 U /L Blocking Antisense RISC Loading Without Altering the 2 F/2 OMe/PS Content Mitigates Hepatotoxicity R a t A L T Dose: 30 mg/kg Regimen: q2d x 6 Necropsy: Day R e fe re n c e ra n g e 0 R IS C lo a d in g b lo c k S a lin e s ir N A -1 s ir N A -2 RISC loading block - + * ^ * # 9
10 u g A S / g liv e r n g A S / g liv e r Changing sirna Chemical Modification Pattern Does Not Reduce Liver Exposure or RISC Loading Dose: 100 mg/kg Regimen: qw x 9 Necropsy: Day 58 ESC Advanced ESC Illustrative design Altered modification pattern for improved metabolic stability R a t L iv e r E x p o s u r e R a t R IS C L o a d in g E S C Ad v a n c e d E S C 0 E S C Ad v a n c e d E S C 10
11 U /L Changing sirna Chemical Modification Pattern Does Not Mitigate Hepatotoxicity R a t A L T Dose: 100 mg/kg Regimen: qw x 9 Necropsy: Day R e fe re n c e ra n g e 0 ESC S a lin e E S C Ad v a n c e d E S C Advanced ESC # * # * 11
12 Potential Causes of Hepatotoxicity in Rodent Toxicity Studies RISC loading Illustrative design 1. Non-RNAi drug effects e.g. protein binding On-target binding Full sequence match mrna cleavage RISC mrna 3 -UTR 2. Competition for Ago binding with mirnas Off-target binding Partial sequence match 3. RNAi-mediated off-target activity 12 Desired on-target activity
13 Relative Target Protein Level Reversir Platform Achieves Tailored Control of RNAi Pharmacology ASGPR 120% 100% Reversir Functional RISC 80% mrna target 60% 40% 20% No Reversir mrna cleavage Inactive RISC 0% mg/kg GalNAc-siRNA 0.1 mg/kg GalNAc-Reversir Time (Days) 13
14 u g A S / g liv e r n g A S / g liv e r Blocking RISC-Loaded Antisense Strand with Reversir Does Not Reduce Liver Exposure or RISC Loading Prevention Reversir sirna ( ) 3-10 mg/kg 30 mg/kg Treatment Reversir sirna 3-10 mg/kg 30 mg/kg R a t L iv e r E x p o s u r e R a t R IS C L o a d in g Targeting Ctr - Targeting Ctr Targeting Ctr RVR sirna 1 - Targeting Ctr - Targeting Ctr Targeting Ctr RVR sirna 14
15 U /L Treatment U /L Prevention U /L Reversing Activity of the RISC-Loaded Antisense Strand Mitigates Hepatotoxicity R a t G L D H + Ctr RVR + Targeting RVR 5 0 R eference range Targeting - Targeting Ctr RVR - 1 sirna R a t G L D H * * * ^ * # * * # R eference range 0 - Targeting - Targeting Ctr RVR - 2 sirna # R a t G L D H R eference range Targeting - Targeting Ctr RVR - 3 sirna
16 u g A S / g liv e r u g A S / g liv e r Swapping Seed Regions Does Not Reduce Liver Exposure or RISC Loading Dose: 30 mg/kg Regimen: q2d x 6 Necropsy: Day 15 Illustrative design R a t L iv e r E x p o s u r e R a t R IS C L o a d in g Toxic Non-toxic Non-toxic Toxic Seed Toxic Non-toxic Toxic Non-toxic Non-seed Parent Seed swap 0 Toxic Non-toxic Non-toxic Toxic Seed Toxic Non-toxic Toxic Non-toxic Non-seed Parent Seed swap 16
17 Non-toxic U /L NON-SEED Toxic Swapping Seed Regions Mitigates Hepatotoxicity Dose: 30 mg/kg Regimen: q2d x 6 Necropsy: Day 15 Toxic SEED Non-toxic R a t A L T # * * R e fe re n c e ra n g e 0 S a lin e btoxic a d C 5Non-toxic g o o d Cg 5oNon-toxic o d s e eb da d stoxic e e d Seed Toxic Non-toxic Toxic Non-toxic Non-seed Parent Seed swap * * # 17
18 GalNAc-siRNA Conjugates Can Cause Seed-Mediated Off-Targets at High Doses RNAseq in Rat Hepatocytes (24 hrs, 10 nm) sirna-1 65 sirna Downregulated genes Antisense seed enrichment Sense seed enrichment Upregulated genes Antisense seed enrichment Sense seed enrichment sirna-1 p < 2.2e-16 p = p = sirna-2 p < 2.2e-16 p = p = p =
19 sirna-2 sirna-1 RNAi Activity is Driving Gene Dysregulation In Vivo at High Doses RNAseq in Rat Liver (24 hrs, 50 mg/kg) - RISC loading block % % % % 19 sirna-1 sirna-2 RISC Loading Block Downregulated genes Antisense seed enrichment Sense seed enrichment Upregulated genes Antisense seed enrichment Sense seed enrichment - p = 1.25e-03 p = p = 1 p = p = 1 (NA) p = 1 (NA) p = 1 p = p = 2.06e-10 p = p = 1 p = p = 1 p = 1 p = 1 p = 1
20 Conclusions 3 -UTR Off-target binding Partial sequence match RNAi-mediated offtarget activity Antisense strand-driven RNAi-mediated hybridization-based off-target effects, not chemical modifications, are a major driver of hepatotoxicity of a subset of GalNAc-siRNA conjugates that fail in rodent toxicity studies at >100x PD dose Careful selection of "good actor" sirnas is an important part of identifying optimal sirna molecules for clinical development 20
21 Thank You! 21 Nonclinical Safety and Bioanalysis Carole Harbison Yongfeng Jiang Onur Yilmaz Michael Placke Natalie Keirstead Kirk Brown Brenda Carito Samantha Chigas Sean Dennin Kristin Fong Paul Gedman Toni Hayes Emma Henchy Lauren Moran Elena Ooms Rachel Peters Kristina Perry Kellie Sawyer Catrina Wong Research Adam Castoreno Rubina Parmar Mark Schlegel Svetlana Shulga-Morskaya Huilei Xu Ivan Zlatev Martin Maier Vasant Jadhav Terence Cawley Klaus Charisse Anna Bisbe Rajeev Kallanthottathil Ryan Malone Mano Manoharan Jonathan O'Shea Nate Taneja Christopher Theile Jeff Rollins Stacy Seide
ESC+ design minimizes the off-target potential and further maximizes the therapeutic index of GalNAc-siRNA conjugates
ESC+ design minimizes the off-target potential and further maximizes the therapeutic index of GalNAc-siRNA conjugates 4th Annual Meeting of the Oligonucleotide Therapeutics Society, Oct. 2, 28 Martin Maier,
More informationPlatform Advances in RNAi Therapeutics. RNAi Roundtable August 23, 2017
Platform Advances in RNAi Therapeutics RNAi Roundtable August 23, 2017 Agenda Welcome Josh Brodsky, Associate Director, Investor Relations & Corporate Communications Introduction Akshay Vaishnaw, M.D.,
More informationDrug Metabolism and Pharmacokinetic (DMPK) Properties of sirna-galnac Conjugates
Drug Metabolism and Pharmacokinetic (DMPK) Properties of sirna-galnac Conjugates Anshul Gupta, Lead Scientist DSM, Alnylam Pharmaceuticals, Cambridge, MA DIA/FDA Oligonucleotide Based Therapeutic Conference,
More informationTIDES 2014 GalNAc-siRNA with Enhanced Stabilization Chemistry: ESC-GalNAc-siRNA. May 14, 2014 Muthiah Manoharan
TIDES 2014 GalNAc-siRNA with Enhanced Stabilization Chemistry: ESC-GalNAc-siRNA May 14, 2014 Muthiah Manoharan Agenda sirna-galnac Conjugates: Background Standard Template Chemistry (STC)» Human POC of
More informationPlatform Advances in RNAi Therapeutics June 26, 2018
Platform Advances in RNAi Therapeutics June 26, 2018 1 2018 Alnylam Pharmaceuticals, Inc. Agenda Welcome Christine Lindenboom, Vice President, Investor Relations & Corporate Communications Introduction
More informationPre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated with Alpha-1 Antitrypsin Deficiency
Pre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated with Alpha-1 Antitrypsin Deficiency A. Sehgal 1, K. Blomenkamp 2, K Qian 1, A. Simon 1, P. Haslett, S. Barros 1, J. Teckman 2 May
More informationHepatocyte-Targeted RNAi Therapeutics: A Reproducible and Modular Platform for Innovative Medicines
Hepatocyte-Targeted RNAi Therapeutics: A Reproducible and Modular Platform for Innovative Medicines Laura Sepp-Lorenzino January 28, 2016 1 2016 Alnylam Pharmaceuticals, Inc. Alnylam Forward Looking Statements
More informationHepatocyte-Targeted RNAi Therapeutics: A Reproducible and Modular Platform for Innovative Medicines
Hepatocyte-Targeted RNAi Therapeutics: A Reproducible and Modular Platform for Innovative Medicines Laura Sepp-Lorenzino January 28, 2016 1 2016 Alnylam Pharmaceuticals, Inc. Alnylam Forward Looking Statements
More information12th US-Japan Symposium on Drug Delivery Systems Advances in Systemic Delivery of RNAi Therapeutics. Martin Maier
12th US-Japan Symposium on Drug Delivery Systems Advances in Systemic Delivery of RNAi Therapeutics Martin Maier December 18, 213 RNAi Therapeutics Harness natural pathway» Catalytic mechanism» Mediated
More informationSafety Assessment of Oligonucleotide Constructs. Scott P. Henry, VP, Preclinical Development, Isis Pharmaceuticals, Inc., USA
Safety Assessment of ligonucleotide Constructs Scott P. Henry, VP, Preclinical Development, Isis Pharmaceuticals, Inc., USA Drug Development of 2 ME AS Platform Technology 2 Platform technologies offer
More informationAptamer-Functionalized Delivery System for Osteogenic sirnas to Achieve Osteoblast- Specific RNA Interference for Bone Anabolic Therapy
Aptamer-Functionalized Delivery System for Osteogenic sirnas to Achieve Osteoblast- Specific RNA Interference for Bone Anabolic Therapy Chao Liang 1,2, Baosheng Guo 1, Heng Wu 1, Lingqiang Zhang 2, Aiping
More informationAlnylam Pharmaceuticals R&D Day
Alnylam Pharmaceuticals R& ay ecember 12, 2014 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933
More informationStifel Nicolaus Healthcare Conference. September 2012
Stifel Nicolaus Healthcare Conference September 212 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning of Section 27A of the Securities Act of
More informationRobust and Durable Target Silencing in the CNS with sirna Conjugates
Robust and Durable Target Silencing in the CNS with sirna Conjugates Stuart Milstein October 2, 2018 1 2018 Alnylam Pharmaceuticals, Inc. Alnylam Forward Looking Statements This presentation contains forward-looking
More informationWFH 2014 World Congress Medical Free Paper 8 ALN AT3: An Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia
WFH 214 World Congress Medical Free Paper 8 ALN AT3: An Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia May 15, 214 Akin Akinc, PhD Antithrombin and ALN-AT3 Program
More informationPreclinical Development of Biologics: Case-by-case, so get off of my case!
Preclinical Development of Biologics: Case-by-case, so get off of my case! Northeast Chapter SOT David Jacobson-Kram, Ph.D., DABT Office of New Drugs Center for Drug Evaluation and Research FDA October
More informationWelcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications
Welcome to R&D Day! Christine Lindenboom VP, Investor Relations & Corporate Communications 1 Alnylam Forward Looking Statements This presentation contains forward-looking statements, within the meaning
More informationAccelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective
Accelerating Therapeutic Development through a look at current Regulatory Applications A Non-Clinical Perspective Imran M. Khan, Ph.D. Division of Psychiatry Center for Drug Evaluation and Research FDA
More informationTherapeutic RNA delivery
Therapeutic RNA delivery 05/02/2017 TIDES Dr. Adrien Weingärtner Head of Technology Development Forward looking statements THE INFORMATION CONTAINED IN THIS PRESENTATION IS BEING SUPPLIED AND COMMUNICATED
More informationAlnylam Pharmaceuticals July 22, 2014
Alnylam Pharmaceuticals July 22, 2014 Corporate Speakers Joshua Brodsky;Alnylam Pharmaceuticals;Manager - IR and Corporate Communications Laurence Reid;Alnylam Pharmaceuticals;SVP and Chief Business Officer
More informationNUVEC. Non-viral adjuvant delivery system for vaccines and cancer treatments. Allan Hey, Head of CMC, N4 Pharma Ltd
NUVEC Non-viral adjuvant delivery system for vaccines and cancer treatments Allan Hey, Head of CMC, N4 Pharma Ltd 1 N4 Pharma plc o Established in 2014 o Listed on Alternative Investment Market (AIM) in
More informationAdvances in RNAi Therapeutics at Arrowhead Pharmaceuticals March 1, 2018 Zhen Li
Advances in RNAi Therapeutics at Arrowhead Pharmaceuticals March 1, 2018 Zhen Li Outline RNA Interference Arrowhead Pharmaceuticals RNAi Platform Development Preclinical Candidates ARO-AAT ARO-HBV 2 Small
More informationTechnology Overview. Figure 1. asirna structure
BMT, Inc. Technology Overview Small interfering RNAs (sirnas) are short, double-stranded RNAs (dsrnas) that mediate efficient gene silencing in a sequence-specific manner. The specific cleavage of mrna
More informationLaura Andrews, PhD, DABT, Fellow ATS
Laura Andrews, PhD, DABT, Fellow ATS What is a Biologic? From PHS Act of 1944 A biologic is any virus, toxin, antitoxin, therapeutic serum, vaccine, blood, blood component or derivative, allergenic products
More informationNanosize: What Can We Learn about Nonclinical Evaluations? Abby Jacobs CDER/FDA 1/2014 NOT official CDER/FDA policy
Nanosize: What Can We Learn about Nonclinical Evaluations? Abby Jacobs CDER/FDA 1/2014 NOT official CDER/FDA policy The Interplay Between Characterization and Toxicology (a) How do we know the material
More information06/03/2009. Overview. Preclinical Support for Exploratory Phase I Clinical Trials. Micro-dosing IND. Pharmacological Active Single Dose IND
Preclinical Support for Exploratory Phase I Clinical Trials Clive Joseph, DSRD Sandwich Overview Identify the most appropriate development paradigm - traditional vs alternative IND approach Confidence
More informationIntegrating Molecular Toxicology Earlier in the Drug Development Process
Integrating Molecular Toxicology Earlier in the Drug Development Process Jonathan Hitchcock Molecular Toxicology, Drug Safety R&D Pfizer Global Research & Development Sandwich, Kent UK 4.5 4.0 3.5 3.0
More informationCreating Highly Efficacious ADCs for Low-Expression Targets While Improving Therapeutic Index TIM LOWINGER, PHD
Creating Highly Efficacious ADCs for Low-Expression Targets While Improving Therapeutic Index TIM LOWINGER, PHD CSO Mersana Therapeutics VC-backed Biotech in Cambridge, MA Investors: NEA, Pfizer, Fidelity,
More informationIntroduction to Drug Design and Discovery
Introduction to Drug Design and Discovery Course: Drug Design Course code: 0510412 Dr. Balakumar Chandrasekaran Dr. Bilal Al-Jaidi Assistant Professors, Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy,
More informationThe Exploratory IND (Phase 0) Concept
The Exploratory IND (Phase 0) Concept Joseph C. Hung Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA In recent years, the costs for drug research and development (R&D) have escalated despite
More informationGlobal Development Challenges: Classical and Advanced Therapy Medicinal products
Global Development Challenges: Classical and Advanced Therapy Medicinal products Beatriz Silva Lima imed, Lisbon University and Infarmed,, Portugal CHMP, CAT, SAWP Member and SWP Chair NONCLINICAL STUDIES
More informationCell type-specific delivery of sirnas with aptamer-sirna chimeras
Cell type-specific delivery of sirnas with aptamer-sirna chimeras Sullenger, B. A. et al Duke Center for Translational Research, Duke University Nature Biotechnology, 2006, 24, 1005 Julia Vargas November
More informationUse of Antisense Oligonucleotides for the Treatment of Inheritable Rare Disorders. C. Frank Bennett Isis Pharmaceuticals
Use of Antisense ligonucleotides for the Treatment of Inheritable Rare Disorders C. Frank Bennett Isis Pharmaceuticals Agenda Review different antisense strategies Delivery of oligonucleotides to the skin,
More informationPreclinical Development of ALN-AS1, an Investigational RNAi Therapeutic for the Treatment of the Hepatic Porphyrias
Preclinical Development of ALN-AS1, an Investigational RNAi Therapeutic for the Treatment of the Hepatic Porphyrias Amy Chan, Abigail Liebow, Makiko Yasuda, Scott Barros, Tim Racie, Martin Maier, Satya
More informationEvaluation of RNA interference (RNAi) in Skin
Evaluation of RNA interference (RNAi) in Skin Next Generation in RNAi Pamela A. Pavco VP Pharmaceutical Development 3rd International SCAR Club Meeting March 26, 2010 www.rxipharma.com Massachusetts, USA
More informationHow Targets Are Chosen. Chris Wayman 12 th April 2012
How Targets Are Chosen Chris Wayman 12 th April 2012 A few questions How many ideas does it take to make a medicine? 10 20 20-50 50-100 A few questions How long does it take to bring a product from bench
More informationM&S in early development (to support FTiM)
Modelling and simulation support for design of First-in- Man studies: the MEL approach Hélène Karcher, Stacey Tannenbaum, Philip Lowe Modelling & Simulation, Novartis Pharma G EM-EFPI Workshop on the role
More informationGene-silencing oligonucleotides: Innovative design of oligonucleotides with enhanced efficacy and RNAilike mechanism of action
Gene-silencing oligonucleotides: Innovative design of oligonucleotides with enhanced efficacy and RNAilike mechanism of action Nicola La Monica, Ekambar R. Kandimalla, Sudhir Agrawal Idera Pharmaceuticals,
More informationUnique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations. [mabs -monoclonal antibodies ] Peter Lloyd
Unique PK-PD properties of biotechnology-based therapeutics [mabs] and First In Human dose considerations [mabs -monoclonal antibodies ] Peter Lloyd Head of Pharmacokinetics-Pharmacodynamics Novartis Biologics
More informationMetabolite ID. Introduction
Metabolite ID Introduction Drug metabolism plays an increasingly important role in the drug discovery and development process. For the early discovery phase, investigating drug metabolism is intended to
More informationWhat s the difference? Challenges in pre-clinical development of biologics
Biologics vs Small MW NCEs What s the difference? Challenges in pre-clinical development of biologics Peter Lloyd Joint Conference of EU Human Pharmacological Societies and 20 th Anniversary of AGAH 31
More informationJoint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products
Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Table of contents 1.Introduction...2 2.Scope...3 3.Discussion...4 3.1. Chemistry, manufacturing, and controls...4
More informationINTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of
More informationTrends in Medical Research -
RNA Interference Tel : 02-2267-1740 / E-mail : kimys@inje.ac.kr, RNAi (RNA or RNA silencing) ( ) DNA small RNA (srnas) mrna,. DNA small RNA. DNA RNA small RNA. small RNA mirna (microrna), RNA RNAi. 1993
More informationHistory of RNAi Therapeutic Delivery at Arrowhead Pharmaceuticals
History of RNAi Therapeutic Delivery at Arrowhead Pharmaceuticals James C. Hamilton MD, MBA 2/22/2018 1 Arrowhead Pharmaceuticals Company focused on developing sirna therapeutics Working in RNAi for over
More informationOSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward -
OSWG s Role in Shaping the Regulatory Development of Oligos - A Potential Model for Moving Forward - David H. Schubert VP, Regulatory and Quality Outline What? Background and History Who? How? OSWG Committees
More informationAn Update on the Development of sd-rxrna for Retinoblastoma Therapy
NASDAQ: RXII An Update on the Development of sd-rxrna for Retinoblastoma Therapy Next Generation in RNAi Michael Byrne, PhD ARVO May 8, 214 2 Forward Looking Statements This presentation contains forward-looking
More informationComments and suggestions from reviewer
Comments and suggestions from reviewer Page 1 of 13 Title: WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology: WHO/rDNA_DRAFT/12
More informationMarina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics
Marina Biotech Monetizes UNA Intellectual Property Estate through Agreement with Arcturus Therapeutics CAMBRIDGE, MA, August 14, 2013 Marina Biotech, Inc. (OTC Pink: MRNA): Assigns Unlocked Nucleobase
More informationS9 Nonclinical Evaluation for Anticancer Pharmaceuticals
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create
More informationFirst-in-human clinical trials Behind the scenes
First-in-human clinical trials Behind the scenes Dr Douglas Francis BVSc MVSc PhD, UK/European registered toxicologist Principal Regulatory Toxicologist Prior to review by Bellberry Ethics Committee Identify
More informationsirna Overview and Technical Tips
1 sirna Overview and Technical Tips 2 CONTENTS 3 4 5 7 8 10 11 13 14 18 19 20 21 Introduction Applications How Does It Work? Handy Tips Troubleshooting Conclusions Further References Contact Us 3 INTRODUCTION
More informationComparative Study of Regulatory Requirements for Biologics Filing in United States and European Union
Comparative Study of Regulatory Requirements for Biologics Filing in United States and European Union Mr. Shashi Kumar Yadav Assistant Professor Sri Indu Institute of Pharmacy Hyderabad Outline Introduction
More information参考資料. Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products. Draft
参考資料 1 2 3 4 5 Joint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products Draft 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Table of contents 1.
More informationTITLE: Highly specific targeting of the TMPRSS2/ERG fusion gene in prostate cancer using liposomal nanotechnology
AD Award Number: W81XWH-09-1-0385 TITLE: Highly specific targeting of the TMPRSS2/ERG fusion gene in prostate cancer using liposomal nanotechnology PRINCIPAL INVESTIGATOR: Bulent Ozpolat, M.D., Ph.D. Michael
More informationValue Correct Answer Feedback. Student Response. A. Dicer enzyme. complex. C. the Dicer-RISC complex D. none of the above
1 RNA mediated interference is a post-transcriptional gene silencing mechanism Which component of the RNAi pathway have been implicated in cleavage of the target mrna? A Dicer enzyme B the RISC-siRNA complex
More informationPharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
More informationDetection of toxicity to reproduction for human pharmaceuticals. Explanatory slides agreed by EWG members
Detection of toxicity to reproduction for human pharmaceuticals Explanatory slides agreed by EWG members 2 October 2017 International Council for Harmonisation of Technical Requirements for Pharmaceuticals
More informationGuideline on the non-clinical requirements for radiopharmaceuticals
1 2 3 15 November 2018 EMA/CHMP/SWP/686140/2018 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Draft Draft agreed by Safety Working Party October 2018 Adopted by CHMP for release for consultation
More informationControl of Eukaryotic Gene Expression (Learning Objectives)
Control of Eukaryotic Gene Expression (Learning Objectives) 1. Compare and contrast chromatin and chromosome: composition, proteins involved and level of packing. Explain the structure and function of
More informationRe: Docket No. FDA-2009-D-0006 S9 Nonclinical Evaluation for Anticancer Pharmaceuticals
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org April 20, 2009 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville,
More informationExploratory clinical trials workshop
Exploratory clinical trials workshop Yves Donazzolo, Grenoble / Lyon Dominique Tremblay, Paris AGAH / Club Phase I meeting Lyon, April 28 & 29, 2009 Topics Introduction Definitions Nonclinical safety studies
More informationLearning Objectives. Define RNA interference. Define basic terminology. Describe molecular mechanism. Define VSP and relevance
Learning Objectives Define RNA interference Define basic terminology Describe molecular mechanism Define VSP and relevance Describe role of RNAi in antigenic variation A Nobel Way to Regulate Gene Expression
More informationDevelopment of Novel Therapies Using Advanced GalNAc-siRNA Technology
PT Congress, March 27, 2018 Development of Novel Therapies Using Advanced GalNAc-siRNA Technology Marie Wikström Lindholm, PhD, Head of Technology Innovation Forward looking statements The information
More informationCase Study: Identification and Development of SLN124, a Conjugated GalNAc-siRNA Therapeutic for the Treatment of Iron Overload Disorders
OPT Congress, 28 March 2018 Case Study: Identification and Development of SLN124, a Conjugated GalNAc-siRNA Therapeutic for the Treatment of Iron Overload Disorders Torsten Hoffmann, PhD, Chief Operating
More information! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General
! Background! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs)! 5 Approaches (Table 3) for:! Microdose trials (7.1)! Single-Dose (SD) Trials at Sub-therapeutic Doses or Into the
More informationDisclosures: C. Liang: None. B. Guo: None. H. Wu: None. L. Dang: None. Z. Yang: None. L. Zhang: None. A. Lu: None. G. Zhang: None.
Development Of Aptamer-functionalized Osteoblast-targeting Lipid Nanoparticles Encapsulating Osteogenic Sirnas For Bone Anabolic Therapy: Investigation Of Tissue-selective Distribution, Dose-response Pattern
More informationAgenda. Welcome. Introduction. Review of Interim ALN-CC5 Phase 1/2 Data. Q&A Session
A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1/2 Study Results June 11, 2016 1 Agenda
More informationUpdate on GalNAc-DsiRNA-EX Conjugates. Bob D. Brown, Ph.D. CSO, SVP Research Dicerna Pharmaceuticals TIDES 2016, USA
Update on GalNAc-DsiRNA-EX Conjugates Bob D. Brown, Ph.D. CS, SVP Research Dicerna Pharmaceuticals TIDES 2016, USA 2 Forward-looking statements This information may contain projections and other forward
More informationCHAPTER 4. Milestones of the drug discovery
CHAPTER 4 Milestones of the drug discovery 4.Milestones of the drug discovery: Highlights the importance of the below critical milestones of the drug discovery and correlated to the current research. 1.
More informationRevidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung. Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität
Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität PD Dr. Elke Röhrdanz Präklinik Fachgebiet Klinische Prüfung
More informationB. Incorrect! Magendie is a person who laid the foundations for animal physiology and pharmacology in the 18 th and 19 th centuries.
Pharmacology - Problem Drill 01: Introduction to Pharmacology Question No. 1 of 10 1. is the science of drug preparation and medical use of drugs. Question #01 (A) Pharmacogenomics (B) Magendie (C) Materia
More informationReflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications
17 March 2011 EMA/CHMP/SWP/100094/2011 Committee for Medicinal Products for Human Use (CHMP) Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications Draft
More informationGalNAc-DsiRNA-EX Conjugate Development. Bob D. Brown, Ph.D. CSO, SVP Research Dicerna Pharmaceuticals TIDES 2016, USA
GalNAc-DsiRNA-EX Conjugate Development Bob D. Brown, Ph.D. CS, SVP Research Dicerna Pharmaceuticals TIDES 216, USA 2 Forward-looking statements This information may contain projections and other forward
More informationStrategy for Selecting NAb Assay Format
Strategy for Selecting NAb Assay Format European Bioanalysis Forum 27Sept2016 Jim McNally, Ph.D. Associate Director, Global Early Development Head of Clinical Bioanalytics Merck KGaA AAPS Working Group
More informationAn Integrated Approach to PK/PD/IG/Safety for Biologics
An Integrated Approach to PK/PD/IG/Safety for Biologics Moderator: Sanela Bilic, PharmD, MBA Novartis Oncology, Clinical Pharmacology Speakers: Sebastian Spindledreher, PhD, DMPK-Bx, Novartis AG Jennifer
More informationVELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS
VELTIS : INNOVATIVE ALBUMIN BASED TECHNOLOGY FOR HALF- LIFE EXTENSION AND OPTIMIZATION OF BIOTHERAPEUTICS Dr Mikael Bjerg Caspersen Industrial Biotechnology Conference August 10 th 2015 INNOVATIVE TECHNOLOGY
More informationJuvenile toxicity studies with biopharmaceuticals : considerations and current practices
Juvenile toxicity studies with biopharmaceuticals : considerations and current practices Shaun Maguire Toxicologist, Biologics Safety Assessment, MedImmune, Cambridge, UK maguires@medimmune.com AGAH Workshop
More informationCowen Healthcare presentation March 13th 2018
Cowen Healthcare presentation March 13th 2018 Disclaimer The information contained in this presentation is being supplied and communicated to you on a confidential basis solely for your information and
More informationRNA Interference (RNAi) (see also mirna, sirna, micrna, shrna, etc.)
Biochemistry 412 RNA Interference (RNAi) (see also mirna, sirna, micrna, shrna, etc.) April 8, 2008 The Discovery of the RNA Interference (RNAi) Phenomenon 1. Gene-specific inhibition of expression by
More informationUtility of Branched DNA Hybridization Methodology for the Quantitation of Oligonucleotides
Utility of Branched DNA Hybridization Methodology for the Quantitation of Oligonucleotides Laboratory Sciences, MPI Research, A Charles River Company Amy Smith, BA, Senior Director, Bioanalytical/Analytical
More informationICH S9 -Nonclinical Evaluation for Anticancer Pharmaceuticals: Questions and Answers
ICH S9 -Nonclinical Evaluation for Anticancer Pharmaceuticals: Questions and Answers May 2018 International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use 1 Legal
More informationAn RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
SUPPLEMENTARY INFORMATION An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia Alfica Sehgal 1, Scott Barros 1, Lacramioara Ivanciu 2, Brian
More informationChallenges in Developing a Neutralizing Antibody Assay for a Cyno Toxicology Study
Challenges in Developing a Neutralizing Antibody Assay for a Cyno Toxicology Study Robin Marsden, Sr. Mgr., Bioanalytical Sciences, La Jolla Pharmaceutical Co. Kristine de Dios, M.S., Scientist, Preclinical
More informationADCS, WHAT IS INDUSTRY DOING TODAY? AN OVERVIEW
ADCS, WHAT IS INDUSTRY DOING TODAY? AN OVERVIEW Johannes Stanta PhD Scientific Manager, Bioanalysis EBF ADC Training day June 2017 Copyright 2017 Covance. All Rights Reserved ADC Bioanalytical PK Assays
More informationIntroduction to Drug Development in Commercializing Biomedical Technology
Introduction to Drug Development in Commercializing Biomedical Technology Kevin W. Hunt, Ph.D. Director of Biopharmaceutical Product Development Office of Technology Development and Head of Translational
More informationJoint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products
1 2 3 17 January 2013 EMA/CHMP/13099/2013 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Joint MHLW/EMA reflection paper on the development of block copolymer micelle Agreed by Nanomedicines
More informationDrug Discovery and Development PHG 311. Prof. Dr. Amani S. Awaad
Drug Discovery and Development PHG 311 Prof. Dr. Amani S. Awaad Professor of Pharmacognosy Pharmacognosy Department, College of Pharmacy Salman Bin Abdulaziz University, Al-Kharj. KSA. Email: amaniawaad@hotmail.com
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/32775/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE ON SIMILAR BIOLOGICAL
More information21st Annual International Conference on Drug-Drug Interactions. Zach Mitts Northwest Account Manager
21st Annual International Conference on Drug-Drug Interactions Zach Mitts Northwest Account Manager How memorable can a 5-minute presentation be? COMPANY HISTORY From the work of our Founder, Dr. Andrew
More informationA Survey of Genetic Methods
IBS 8102 Cell, Molecular, and Developmental Biology A Survey of Genetic Methods January 24, 2008 DNA RNA Hybridization ** * radioactive probe reverse transcriptase polymerase chain reaction RT PCR DNA
More informationFrom Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager
From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,
More informationRXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation Next Generation in RNAi Jefferies 2014 Global Healthcare Conference June 3, 2014 NASDAQ: RXII 2 Forward Looking Statements This presentation contains forward-looking statements
More informationREGULATION OF PROTEIN SYNTHESIS. II. Eukaryotes
REGULATION OF PROTEIN SYNTHESIS II. Eukaryotes Complexities of eukaryotic gene expression! Several steps needed for synthesis of mrna! Separation in space of transcription and translation! Compartmentation
More informationArtificial Nucleic Acids -Their Developments and Recent Applications
Artificial Nucleic Acids -Their Developments and Recent Applications Bioorganic Chemistry Laboratory D2 Kenichiro Ito Organic Seminar 2012/5/7 1 Nucleic acids play central roles in life Replication Transcription
More informationPK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis
PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis
More informationAdvanced GalNAc-siRNA Platform and Its Therapeutic Applications
TIDES: Oligonucleotide and Peptide Therapeutics, 07-10 May 2018 Advanced GalNAc-siRNA Platform and Its Therapeutic Applications Torsten Hoffmann, PhD, Chief Scientific Officer Forward looking statements
More informationSupplementary Figure 1. In vitro activity screen of PLK1 sirna sequences. Activity of native PLK1 sirna sequences targeting human PLK1 mrna were
Supplementary Figure legends Supplementary Figure 1. In vitro activity screen of PLK1 sirna sequences. Activity of native PLK1 sirna sequences targeting human PLK1 mrna were assessed in the HT29 cell viability
More informationTherapeutic & Prevention Application of Nucleic Acids
Therapeutic & Prevention Application of Nucleic Acids Seyed Amir Hossein Jalali Institute of Biotechnology and Bioengineering, Isfahan University Of Technology (IUT). 30.7.2015 * Plasmids * DNA Aptamers
More informationSureSilencing sirna Array Technology Overview
SureSilencing sirna Array Technology Overview Pathway-Focused sirna-based RNA Interference Topics to be Covered Who is SuperArray? Brief Introduction to RNA Interference Challenges Facing RNA Interference
More information